Fellows Shawn E, Cipriano Gabriela C
Assistant Professor, Department of Pharmacy Practice Wegmans School of Pharmacy at St. John Fisher College, Rochester, NY.
Associate Professor, Department of Pharmacy Practice Wegmans School of Pharmacy at St. John Fisher College, Rochester, NY.
P R Health Sci J. 2019 Sep;38(3):189-191.
The aim of this study was to identify potential disparities between point-of-care testing (POCT) and laboratory hemoglobin A1c (HbA1c) reporting at a Federally Qualified Health Center (FQHC).
The electronic medical record was reviewed to identify POCT HbA1c done at a FQHC and centralized laboratory venous HbA1c performed on the same day. Manual data extraction was used to identify potential variables that could account for disparities between POCT and laboratory testing.
A total of 42 samples in 40 patients were identified. The median HbA1c difference was 1.5 mmol/mol (0.15%) and ranged from -26 to 52 mmol/mol (-2.4 to 4.8%). Of the patients in the study, two had underlying comorbidities that could affect the POCT HbA1c.
Point-of-care HbA1c testing should not be used in solidarity to diagnosis pre-diabetes and diabetes. When using HbA1c results to guide therapy, self-monitoring of blood glucose and symptoms of both hypo- and hyperglycemia should be correlated to help determine appropriate therapy.
本研究旨在确定联邦合格健康中心（FQHC）即时检验（POCT）与实验室血红蛋白A1c（HbA1c）报告之间的潜在差异。
回顾电子病历，以识别在FQHC进行的POCT HbA1c检测以及同一天在中心实验室进行的静脉血HbA1c检测。采用手动数据提取来识别可能导致POCT与实验室检测结果差异的潜在变量。
共识别出40例患者的42份样本。HbA1c差异中位数为1.5 mmol/mol（0.15%），范围为-26至52 mmol/mol（-2.4至4.8%）。在研究患者中，有两名患者存在可能影响POCT HbA1c结果的基础合并症。
不应单纯使用即时检验HbA1c来诊断糖尿病前期和糖尿病。在使用HbA1c结果指导治疗时，应将血糖自我监测以及低血糖和高血糖症状相结合，以帮助确定合适的治疗方案。
